Pilot Study on MAGE-C2 as a Potential Biomarker for Triple-Negative Breast Cancer

Figure 4

The MAGE-C2 expression and prognosis of patients with TNBC by Kaplan-Meier method based on immunohistochemistry. (a) DFS; (b) OS; (c) disease recurrence-free survival. Note: DFS: disease-free survival; OS: overall survival; TNBC: triple-negative breast cancer tissues.

(a)

(b)

(c)